



# CONTINUE STRONG PROFITABLE GROWTH


## Disclaimer

This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio Group Corporations' shares.


Group's past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser.

This presentation contains statements that are estimates based on the management's best knowledge at the time they were made. For this reason, they involve a certain amount of inherent risk and uncertainty. The estimates may change in the event of significant changes in general economic conditions.


Our streamlined operating model




Focus on ophthalmology market and carefully exit the noncore businesses



Fully outsourced and scalable manufacturing support well changes in demand



Invest in R&D to ensure competitiveness. Core R&D inhouse while using services providers to fill in with the varying demands on project developments



Using channel partners to cover more than 100 countries


# Growing faster than the market

Revenio has been taking market share with apx 27% CAGR revenue growth rate during 2016-2020 compared to the market growth rate of ~ 4–6%.

When eliminating the impact of the Centervue acquisition the growth rate of the stand-alone businesses has been slightly above 13% during 2016-2020.

We are committed on continued improvement on market share on all product lines and aim to accelerate the organic growth in the future.

We continue to scan the market for any acquisition opportunities for expanding our product portfolio within the ophthalmic diagnostics market.




Our strong balance sheet give us options to shape a more profitable future

The equity level has remained strong over the years.

The adjusted profitability of the company increased during 2020.

The amount of invested capital grew 5x in 2019 after the CenterVue acquisition which is the main driver of the drop in ROI %.




# Steady cash-flow

We aim to continue the positive and steady operating cash flow.

Operating cash flow has developed well over the last years with CAGR 26.0%.

M&A activities may cause larger variances in the investment cash flow like seen in 2019.

Operative cash flow



Dividends

Revenio aims is to pay a sustainable dividend that does not endanger the parent company’s or group’s liquidity.

Revenio plans to keep a strong balance sheet to support any inorganic opportunities that may arise in order to accelerate the profitable growth of the company.



# Outlook for 2021: We remain committed to the financial targets

COVID-19 pandemic continues to cause uncertainty related to the markets.

Growth

Revenio Group’s exchange rate-adjusted net sales are estimated to grow strongly from the previous year

Profitability

Profitability is to remain at a good level without non-recurring items.

Continue strong profitable growth

Robust financial and operating model geared to value creation

Improved organic sales growth

Organic growth backed up with carefully selected and focused inorganic growth opportunities to shape a more profitable future

Digitalization and connected eye care is growing fast, we are targeting to become one of the key players in this development





“WE ASPIRE TO KEEP THE  
WONDERFUL WORLD VISIBLE FOR ALL”

Thank you!  
Questions?